单周期新辅助帕博利珠单抗治疗I-III期错配修复缺陷结肠癌:RESET-C试验
RESET-C试验纳入85例局部dMMR结肠癌患者,接受单周期新辅助帕博利珠单抗(4 mg/kg,最大400 mg,每6周方案)后手术。84例可评估患者中pCR达44%(95%CI 33-55),MPR达57%(95%CI 46-68);中位随访18.4个月,1例复发,OS和DFS分别为98%和96%。
要点
- 单周期新辅助帕博利珠单抗在局部dMMR结肠癌中pCR达44%,MPR达57%。
- 3级不良事件发生率11%,术后30天内2例(2%)死于并发症。
- 内镜图像预测pCR的敏感度77%、特异度93%、准确率86%。
核心结论
- 单周期新辅助帕博利珠单抗使近半数局部dMMR结肠癌手术患者达到pCR。
- 内镜评估可能为未来非手术管理路径中的患者选择提供依据。
研究设计与样本
- RESET-C试验为单臂试验,2023年2月至2024年3月纳入85例局部dMMR结肠癌患者(中位年龄74岁)。
- 所有患者接受单周期帕博利珠单抗(4 mg/kg,最大400 mg,每6周方案),随后术前内镜活检并于3-5周后手术。
- 主要终点为pCR;次要和探索性终点包括MPR、安全性、生存和内镜反应评估。
主要发现
- 84例可评估患者中pCR为44%(37/84;95%CI 33-55),MPR为57%(48/84;95%CI 46-68)。
- 中位随访18.4个月(IQR 16.3-21.1)时1例复发,OS和DFS分别为98%和96%。
- 3级不良事件发生率为11%(9/85;95%CI 3-16),其中3例为治疗相关事件。
- 术后30天内2例(2%)死于并发症。
- 81例中活检预测pCR的敏感度、特异度和准确率分别为68%、75%和72%;76例中内镜图像分别为77%、93%和86%。
临床怎么用
- 对局部dMMR结肠癌可考虑单周期新辅助帕博利珠单抗后手术,pCR率约44%。
- 内镜图像预测pCR准确率较高,可用于评估反应并辅助非手术管理决策。
局限性
- 单臂设计,无对照组。
- 样本量有限(85例),随访时间较短(中位18.4个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Neoadjuvant immune checkpoint inhibition has shown promise in localized deficient mismatch repair (dMMR) colorectal cancer, yet the optimal treatment duration, regimen, and methods for response evaluation remain undefined. This trial aimed to investigate the efficacy and safety of neoadjuvant pembrolizumab for patients with localized dMMR colon cancer. METHODS: Participants received a single cycle of pembrolizumab (4 mg/kg, max 400 mg, every-6-weeks dosing regimen), followed by a preoperative endoscopy with biopsies and surgery 3-5 weeks later. The primary end point was pathologic complete response (pCR); secondary and exploratory end points included major pathologic response (MPR), safety, survival, and endoscopic response assessment. RESULTS: From February 2023 to March 2024, 85 patients (median age 74 years) were enrolled. All received pembrolizumab; one patient declined surgery. Among 84 patients, pCR was achieved in 44% (37 of 84; 95% CI, 33 to 55), and MPR in 57% (48 of 84; 95% CI, 46 to 68). Two (2%) patients died of complications within 30 days of surgery. At a median follow-up of 18.4 months (IQR, 16.3-21.1), one patient had a recurrence, resulting in overall and disease-free survival rates of 98% and 96%. Grade 3 adverse events occurred in 11% of patients (9 of 85; 95% CI, 3 to 16), with three treatment-related events. In 81 patients, the sensitivity, specificity, and accuracy of the biopsies for predicting pCR were 68%, 75%, and 72%, respectively. In 76 patients, the sensitivity, specificity, and accuracy of the endoscopic images for predicting pCR were 77%, 93%, and 86%, respectively. CONCLUSION: A single cycle of neoadjuvant pembrolizumab led to pCR in nearly half of patients undergoing surgery for localized dMMR colon cancer. The utility of endoscopic evaluation may inform future strategies for patient selection in nonoperative management pathways.
引用
- Gögenur I, Justesen TF, Tarpgaard LS, et al. Neoadjuvant Single-Cycle Pembrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C Trial. J Clin Oncol. 2026. PMID: 42085635. doi:10.1200/JCO-25-02274
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。